Tag Archives: aztreonam

Antibiotic Inhalers Galore (Part 1):  More Combinations and Permutations than a Rubik’s Cube

Posted on by — No Comments ↓

There is much interest in inhaled antibiotics these days.  Prima facie, the logic for this approach is compelling: Getting the antibiotic (and a lot of it) directly to the site of infection, while avoiding systemic toxicity, sounds like optimized efficacy Continue reading Antibiotic Inhalers Galore (Part 1):  More Combinations and Permutations than a Rubik’s Cube→

QIDP Drug Update – Part 2:  Categories of Interest

Posted on by — No Comments ↓

According to Janet Woodcock, 63 drugs have been given the “QIDP” designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development.  So we are in fairly close agreement. That Continue reading QIDP Drug Update – Part 2:  Categories of Interest→

Treating GC in the Face of Dwindling Antibiotic Options – (1)

Posted on by — No Comments ↓

Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg [1]. In Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (1)→

Aerosolized Antibiotics & Selling Nebulizers

Posted on by — No Comments ↓

“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics.  Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent Continue reading Aerosolized Antibiotics & Selling Nebulizers→

A GO / NO GO decision:  Delafloxacin Stumbles in Gonorrhea Study

Posted on by — No Comments ↓

The treatment history of N. gonorrhoeae makes for fascinating reading.  This organism has always been able to keep the upper hand in the war of bug versus drug.  Once susceptible to sulfa drugs, to penicillin, tetracyclines and fluoroquinolones, it sequentially Continue reading A GO / NO GO decision:  Delafloxacin Stumbles in Gonorrhea Study→